January 4, 2018 / 9:15 PM / 19 days ago

BRIEF-Regenxbio Provides Year-End 2017 Corporate Update

Jan 4 (Reuters) - Regenxbio Inc:

* REGENXBIO PROVIDES YEAR-END 2017 CORPORATE UPDATE

* - ‍ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018​

* - ‍ANTICIPATE COMPLETING DOSING AND PRESENTING TOPLINE DATA FROM RGX-314 AND RGX-501 TRIALS IN LATE 2018​

* - ‍ENDED 2017 WITH GREATER THAN $175 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​

* SAYS EXPECTS FULL-YEAR 2018 CASH BURN TO BE BETWEEN $85 MILLION AND $95 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below